37.69

0.99% 0.37

After Hours: 37.69

Sutro Biopharma Inc (STRO)

Overview News Price History Option Chain Financials Discussions Forecast

Sutro Biopharma Inc stock is traded at $37.69, with a volume of 149.10K. It is up +0.99% in the last 24 hours and up +57.37% over the past month. Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Previous Close:

$37.32

Open:

$37.5

24h Volume:

149.10K

Relative Volume:

0.74

Market Cap:

$624.44M

Revenue:

$102.48M

Net Income/Loss:

$-191.09M

P/E Ratio:

-2.6137

EPS:

-14.4203

Net Cash Flow:

$-178.93M

1W Performance:

+6.50%

1M Performance:

+57.37%

6M Performance:

+300.02%

1Y Performance:

+296.70%

1-Day Range:

$37.32

$39.50

1-Week Range:

$34.41

$39.74

52-Week Range:

$6.736

$39.74

Sutro Biopharma Inc Stock (STRO) Company Profile

Name

Sutro Biopharma Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

650-392-8412

Address

111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

137

Twitter

@SutroBio

Next Earnings Date

2026-05-14

Latest SEC Filings

STRO's Discussions on Twitter

Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STRO Sutro Biopharma Inc	37.69	618.31M	102.48M	-191.09M	-178.93M	-14.42
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Initiated	Leerink Partners	Outperform
Mar-24-26	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-24-26	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-20-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Jun-16-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-25	Downgrade	BofA Securities	Buy → Underperform
Mar-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Downgrade	Wedbush	Outperform → Neutral
May-08-24	Initiated	BofA Securities	Buy
Nov-09-23	Initiated	Deutsche Bank	Buy
Oct-06-23	Initiated	Oppenheimer	Outperform
Mar-21-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-18-22	Resumed	Wells Fargo	Overweight
Jun-18-21	Initiated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Sep-02-20	Initiated	Jefferies	Buy
Jul-16-20	Initiated	Wells Fargo	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Oct-07-19	Initiated	BTIG Research	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
Apr-29-19	Initiated	H.C. Wainwright	Buy
Oct-22-18	Initiated	JMP Securities	Mkt Outperform
Oct-22-18	Initiated	Piper Jaffray	Overweight
Oct-22-18	Initiated	Wedbush	Outperform

View All

Sutro Biopharma Inc Stock (STRO) Latest News

May 02, 2026

Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat

May 01, 2026

Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program - Insider Monkey

May 01, 2026

Mizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendation - MSN

May 01, 2026

Apr 30, 2026

Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell - Seeking Alpha

Apr 30, 2026

This Palantir Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga

Apr 30, 2026

Mizuho Securities Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo

Apr 30, 2026

Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0% - MarketBeat

Apr 30, 2026

Mizuho Initiates Sutro Biopharma at Outperform With $50 Price Target - marketscreener.com

Apr 30, 2026

STRO Initiated Coverage by Mizuho -- Rating Set at Outperform - GuruFocus

Apr 30, 2026

Mizuho initiates Sutro Biopharma stock coverage with outperform rating By Investing.com - Investing.com India

Apr 30, 2026

Mizuho initiates Sutro Biopharma stock coverage with outperform rating - Investing.com

Apr 30, 2026

Apr 29, 2026

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now - Insider Monkey

Apr 29, 2026

Sutro Biopharma (NASDAQ:STRO) Hits New 1-Year HighWhat's Next? - MarketBeat

Apr 29, 2026

Sutro Biopharma Strengthens Financial Position and Advances ADC Pipeline - HarianBasis.co

Apr 29, 2026

5 Tiny Stocks That Are On Fire Right Now - Insider Monkey

Apr 29, 2026

Apr 28, 2026

Sutro Biopharma (NASDAQ:STRO) Shares Up 5.6%What's Next? - MarketBeat

Apr 28, 2026

Apr 27, 2026

Sutro Biopharma (STRO) price target decreased by 21.62% to 29.58 - MSN

Apr 27, 2026

Apr 26, 2026

Sutro Biopharma prices $110M common stock offering - MSN

Apr 26, 2026

Apr 24, 2026